

# Fabien Reyat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3505443/publications.pdf>

Version: 2024-02-01

150  
papers

6,515  
citations

81900

39  
h-index

76900

74  
g-index

181  
all docs

181  
docs citations

181  
times ranked

11047  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e352-e361.	2.4	5
2	Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors. <i>Reproductive BioMedicine Online</i> , 2022, 44, 1031-1044.	2.4	10
3	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	10.7	148
4	Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants. <i>European Journal of Human Genetics</i> , 2022, , .	2.8	2
5	Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. <i>Cell</i> , 2022, 185, 1189-1207.e25.	28.9	166
6	Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy. <i>Cancers</i> , 2022, 14, 1331.	3.7	2
7	Variation over time of the factors influencing return to work and work capacities after a diagnosis of breast cancer: a study on the behalf of the Seintinelles research network. <i>Supportive Care in Cancer</i> , 2022, 30, 5991-5999.	2.2	5
8	Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.6	2
9	The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS). <i>Cancers</i> , 2022, 14, 2671.	3.7	5
10	No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC. <i>Cancers</i> , 2022, 14, 3080.	3.7	0
11	The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer. <i>Cancers</i> , 2021, 13, 235.	3.7	5
12	HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. <i>Cancers</i> , 2021, 13, 370.	3.7	2
13	The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes. <i>Cancers</i> , 2021, 13, 171.	3.7	6
14	PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. <i>Cancers</i> , 2021, 13, 746.	3.7	9
15	Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore. <i>British Journal of Cancer</i> , 2021, 124, 1421-1427.	6.4	15
16	Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey. <i>Cancers</i> , 2021, 13, 1161.	3.7	4
17	Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1070.	3.7	5
18	Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up Consultation. <i>Cancers</i> , 2021, 13, 2423.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance. <i>Oncogene</i> , 2021, 40, 4019-4032.	5.9	19
20	<scp>OTC</scp> deficiency in females: Phenotypeâ€ˆgenotype correlation based on a 130â€ˆfamily cohort. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1235-1247.	3.6	9
21	Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohortâˆ†. <i>ESMO Open</i> , 2021, 6, 100151.	4.5	13
22	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. <i>Journal of Hematology and Oncology</i> , 2021, 14, 143.	17.0	7
23	CloneSig can jointly infer intra-tumor heterogeneity and mutational signature activity in bulk tumor sequencing data. <i>Nature Communications</i> , 2021, 12, 5352.	12.8	8
24	Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 701620.	2.8	0
25	Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. <i>ESMO Open</i> , 2021, 6, 100316.	4.5	36
26	Breast Magnetic Resonance Image Analysis for Surgeons Using Virtual Reality: A Comparative Study. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1127-1133.	2.1	2
27	Domain-invariant features for mechanism of action prediction in a multi-cell-line drug screen. <i>Bioinformatics</i> , 2020, 36, 1607-1613.	4.1	7
28	Helical tomotherapy for patients presented with implant breast reconstruction in case of adjuvant breast cancer radiotherapy: A single center experience. <i>Breast Journal</i> , 2020, 26, 1436-1438.	1.0	3
29	Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1693-1699.	1.5	10
30	No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis. <i>Cancers</i> , 2020, 12, 2943.	3.7	3
31	Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Cancers</i> , 2020, 12, 3681.	3.7	13
32	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2198-2207.	5.5	21
33	Quality assurance in surgical trials: An improvement is needed. <i>Gynecologic Oncology</i> , 2020, 157, 570-571.	1.4	4
34	Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis. <i>PLoS ONE</i> , 2020, 15, e0234173.	2.5	4
35	Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. <i>PLoS ONE</i> , 2020, 15, e0234191.	2.5	51
36	Theoretical and practical knowledge curriculum for European Breast Surgeons. <i>European Journal of Surgical Oncology</i> , 2020, 46, 717-736.	1.0	12

#	ARTICLE	IF	CITATIONS
37	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	86
38	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. <i>Oncolmmunology</i> , 2020, 9, 1677427.	4.6	8
39	Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1818-1827.	1.5	28
40	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.. <i>Blood</i> , 2020, 135, 360-370.	1.4	80
41	Title is missing!. , 2020, 15, e0234191.		0
42	Title is missing!. , 2020, 15, e0234191.		0
43	Title is missing!. , 2020, 15, e0234191.		0
44	Title is missing!. , 2020, 15, e0234191.		0
45	Predicting Residual Cancer Burden In A Triple Negative Breast Cancer Cohort. , 2019, , .		5
46	Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6731-6741.	7.0	53
47	Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data. <i>PLoS ONE</i> , 2019, 14, e0224143.	2.5	16
48	Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and Blueprint® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.	3.7	6
49	Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach. <i>PLoS ONE</i> , 2019, 14, e0208807.	2.5	10
50	A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. <i>Oncolmmunology</i> , 2019, 8, e1624130.	4.6	23
51	Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an "option"™ but an ethical obligation. <i>ESMO Open</i> , 2019, 4, e000515.	4.5	12
52	Innovative DIEP flap perfusion evaluation tool: Qualitative and quantitative analysis of indocyanine green-based fluorescence angiography with the SPY-Q proprietary software. <i>PLoS ONE</i> , 2019, 14, e0217698.	2.5	17
53	High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. <i>Nature Genetics</i> , 2019, 51, 1060-1066.	21.4	335
54	Tubular and mucinous breast cancer: results of a cohort of 917 patients. <i>Tumori</i> , 2019, 105, 55-62.	1.1	8

#	ARTICLE	IF	CITATIONS
55	Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 379-387.	2.5	20
56	JAK-STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI-ALCL PATHOGENESIS?. <i>Hematological Oncology</i> , 2019, 37, 201-201.	1.7	0
57	Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 111-122.	2.5	16
58	Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data. <i>Blood</i> , 2019, 134, 4021-4021.	1.4	0
59	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2605-2615.	7.0	45
60	Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 295-304.	2.5	54
61	Benefit of adjuvant systemic therapies in HR+ HER2- pT1ab node-negative breast carcinomas. <i>Annals of Oncology</i> , 2018, 29, viii63.	1.2	0
62	Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy. <i>Breast</i> , 2018, 42, 61-67.	2.2	5
63	Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. <i>Nature Immunology</i> , 2018, 19, 885-897.	14.5	152
64	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. <i>American Journal of Pathology</i> , 2018, 188, 2378-2391.	3.8	12
65	Neoadjuvant treatment: the future of patients with breast cancer. <i>ESMO Open</i> , 2018, 3, e000371.	4.5	19
66	Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study. <i>BMJ Open</i> , 2018, 8, e020276.	1.9	35
67	Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 307-316.	2.5	16
68	Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. <i>European Journal of Cancer</i> , 2017, 75, 323-332.	2.8	22
69	Therapeutic escalation " De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB). <i>Breast</i> , 2017, 34, 24-33.	2.2	7
70	Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators. <i>British Journal of Cancer</i> , 2017, 116, 1394-1401.	6.4	17
71	Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. <i>Annals of Oncology</i> , 2017, 28, 2233-2240.	1.2	75
72	Literature review assessing time to adjuvant chemotherapy and long term oncological outcomes between patients undergoing simple mastectomy and immediate reconstruction. <i>European Journal of Surgical Oncology</i> , 2017, 43, S21-S22.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Sentinel lymph node biopsy validation for large tumors. <i>International Journal of Surgery</i> , 2017, 48, 275-280.	2.7	3
74	New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels. <i>Scientific Reports</i> , 2017, 7, 15126.	3.3	7
75	Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 73-81.	2.5	7
76	Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. <i>PLoS ONE</i> , 2017, 12, e0169962.	2.5	4
77	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. <i>PLoS ONE</i> , 2016, 11, e0167397.	2.5	9
78	Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. <i>British Journal of Cancer</i> , 2016, 115, 1024-1031.	6.4	23
79	Breast cancer in young women: Pathologic features and molecular phenotype. <i>Breast</i> , 2016, 29, 109-116.	2.2	30
80	No evidence for TSLP pathway activity in human breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1178438.	4.6	38
81	Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. <i>British Journal of Cancer</i> , 2016, 114, 44-52.	6.4	40
82	Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. <i>Oncolmmunology</i> , 2016, 5, e1061176.	4.6	30
83	p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. <i>Oncogene</i> , 2016, 35, 344-357.	5.9	76
84	Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuantâ„¢ Microarray Based Assay. <i>PLoS ONE</i> , 2016, 11, e0146474.	2.5	34
85	Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application. <i>PLoS ONE</i> , 2016, 11, e0148957.	2.5	9
86	Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. <i>PLoS ONE</i> , 2016, 11, e0159888.	2.5	15
87	Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 48206-48219.	1.8	32
88	Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. <i>Genes and Development</i> , 2015, 29, 2547-2562.	5.9	77
89	Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype. <i>Human Genomics</i> , 2015, 9, 26.	2.9	16
90	Changes in correlation between promoter methylation and gene expression in cancer. <i>BMC Genomics</i> , 2015, 16, 873.	2.8	113

#	ARTICLE	IF	CITATIONS
91	Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Pre-dendritic Cells in Aggressive Disease Subtypes. <i>Cancer Research</i> , 2015, 75, 2775-2787.	0.9	49
92	Outcome of oncoplastic breast-conserving surgery following bracketing wire localization for large breast cancer. <i>Breast</i> , 2015, 24, 370-375.	2.2	8
93	Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. <i>British Journal of Cancer</i> , 2015, 112, 912-917.	6.4	13
94	Association of the number of sentinel lymph nodes harvested with survival in breast cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 52-58.	1.0	14
95	Luminal Progenitors Restrict Their Lineage Potential during Mammary Gland Development. <i>PLoS Biology</i> , 2015, 13, e1002069.	5.6	96
96	Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. <i>Annals of Oncology</i> , 2015, 26, 1704-1709.	1.2	18
97	ARF6-JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion. <i>Journal of Cell Biology</i> , 2015, 211, 339-358.	5.2	126
98	Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. <i>British Journal of Cancer</i> , 2015, 113, 30-36.	6.4	25
99	Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 996-1002.	6.4	21
100	The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. <i>Molecular Oncology</i> , 2015, 9, 657-674.	4.6	74
101	Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population. <i>PLoS ONE</i> , 2015, 10, e0132853.	2.5	44
102	Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0144359.	2.5	27
103	Epigenomic Alterations in Breast Carcinoma from Primary Tumor to Locoregional Recurrences. <i>PLoS ONE</i> , 2014, 9, e103986.	2.5	12
104	Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. <i>Oncogene</i> , 2014, 33, 619-631.	5.9	23
105	Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 2195-2200.	6.4	19
106	A siRNA screen identifies RAD21, EIF3H, CHAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. <i>Carcinogenesis</i> , 2014, 35, 670-682.	2.8	44
107	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	12.4	304
108	Extensive pure ductal carcinoma in situ of the breast: Identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery. <i>Breast</i> , 2014, 23, 97-103.	2.2	20

#	ARTICLE	IF	CITATIONS
109	Plastic surgery for breast conservation therapy: How to define the volume of the tumor bed for the boost?. <i>European Journal of Surgical Oncology</i> , 2014, 40, 830-834.	1.0	31
110	Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 373-381.e4.	2.9	74
111	Prediction of axillary lymph node status in male breast carcinoma. <i>Annals of Oncology</i> , 2013, 24, 370-376.	1.2	18
112	Prospective and Comparative Evaluation of the Toxicity of Adjuvant Concurrent Chemoradiotherapy After Neoadjuvant Chemotherapy for Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 425-429.	1.3	5
113	Skin Lesions after Prophylactic Mastectomy and Immediate Reconstruction. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2013, 1, e82.	0.6	1
114	A large retrospective multicenter study of vaginal melanomas. <i>Melanoma Research</i> , 2013, 23, 138-146.	1.2	24
115	Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5139-5144.	7.1	150
116	The Role of Nipple-Sparing Mastectomy in Breast Cancer. <i>Plastic and Reconstructive Surgery</i> , 2013, 131, 969-984.	1.4	157
117	The Impact of Poly Implant Prothèse Fraud on Breast Cancer Patients. <i>Plastic and Reconstructive Surgery</i> , 2013, 131, 690-695.	1.4	11
118	Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma. <i>PLoS ONE</i> , 2013, 8, e55901.	2.5	26
119	Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. <i>PLoS ONE</i> , 2013, 8, e76496.	2.5	16
120	Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression. <i>Cancer Research</i> , 2012, 72, 4920-4930.	0.9	527
121	Preoperative radio-chemotherapy in early breast cancer patients: Long-term results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2012, 102, 82-88.	0.6	37
122	Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma. <i>European Journal of Surgical Oncology</i> , 2012, 38, 1211-1217.	1.0	9
123	Implant breast reconstruction followed by radiotherapy: Can helical tomotherapy become a standard irradiation treatment?. <i>Medical Dosimetry</i> , 2012, 37, 425-431.	0.9	21
124	Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma. <i>PLoS ONE</i> , 2012, 7, e35184.	2.5	17
125	Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification. <i>PLoS ONE</i> , 2012, 7, e47390.	2.5	18
126	Gastric metastasis of breast cancer: A single centre retrospective study. <i>Digestive and Liver Disease</i> , 2011, 43, 823-827.	0.9	45



#	ARTICLE	IF	CITATIONS
127	Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2 <sup>-</sup> Primary Breast Tumors. <i>American Journal of Pathology</i> , 2011, 179, 564-579.	3.8	42
128	External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement. <i>PLoS ONE</i> , 2011, 6, e27446.	2.5	38
129	Management of Phyllodes Breast Tumors. <i>Breast Journal</i> , 2011, 17, 129-137.	1.0	169
130	Use of deformable image fusion to allow better definition of tumor bed boost volume after oncoplastic breast surgery. <i>Surgical Oncology</i> , 2011, 20, e123-e125.	1.6	21
131	Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1458-1459.	1.2	11
132	SMETHILLIUM: spatial normalization METHOD for ILLumina InfiniUM HumanMethylation BeadChip. <i>Bioinformatics</i> , 2011, 27, 1693-1695.	4.1	10
133	MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing. <i>Cancer Research</i> , 2011, 71, 4443-4453.	0.9	331
134	The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma. <i>PLoS ONE</i> , 2011, 6, e20297.	2.5	105
135	Oncoplastic Breast Surgery for Cancer: Analysis of 540 Consecutive Cases. <i>Plastic and Reconstructive Surgery</i> , 2010, 125, 454-462.	1.4	198
136	Le point sur les signatures moléculaires dans le cancer du sein. <i>Oncologie</i> , 2010, 12, 263-268.	0.7	2
137	A prognostic DNA signature for T1T2 node-negative breast cancer patients. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 1125-1134.	2.8	64
138	Long-term Follow-up for Inflammatory Breast Cancer Patients: Institute Curie Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S158-S159.	0.8	0
139	Prognostic factors for local recurrence following breast-conserving treatment in young women. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1215-1227.	2.4	4
140	8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis. <i>PLoS ONE</i> , 2009, 4, e7239.	2.5	79
141	Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. <i>Anticancer Research</i> , 2009, 29, 1475-82.	1.1	24
142	ESR1 gene amplification in breast cancer: a common phenomenon?. <i>Nature Genetics</i> , 2008, 40, 807-808.	21.4	53
143	Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. <i>BMC Genomics</i> , 2008, 9, 375.	2.8	73
144	A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R93.	5.0	113

#	ARTICLE	IF	CITATIONS
145	Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 7165-7175.	0.9	83
146	Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma <i>In situ</i> of the Breast. <i>Clinical Cancer Research</i> , 2008, 14, 1956-1965.	7.0	148
147	Mesh Erosion After Anterior Prosthetic Reinforcement by Vaginal Route: Risk Factors and Management. <i>Journal of Gynecologic Surgery</i> , 2008, 24, 1-10.	0.1	2
148	Regional copy number-independent deregulation of transcription in cancer. <i>Nature Genetics</i> , 2006, 38, 1386-1396.	21.4	198
149	Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas. <i>Cancer Research</i> , 2005, 65, 1376-1383.	0.9	62
150	Reconstruction after Conservative Treatment for Breast Cancer: Cosmetic Sequelae Classification Revisited. <i>Plastic and Reconstructive Surgery</i> , 2004, 114, 1743-1753.	1.4	103